Vaxcyte (PCVX) Profit After Tax (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Profit After Tax data on file, last reported at -$320.6 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 127.85% year-over-year to -$320.6 million in Q1 2026; TTM through Mar 2026 was -$946.5 million, a 84.28% decrease from a year earlier, with the FY2025 full-year figure at -$766.6 million, down 63.82% from the prior year.
• Profit After Tax for Q1 2026 stood at -$320.6 million, down from -$246.5 million in the prior quarter.
• Over the last five years, Profit After Tax for PCVX reached as high as -$39.0 million in Q1 2022 and fell as low as -$320.6 million in Q1 2026.
• Historically, Profit After Tax has averaged -$128.3 million across 5 years, with a median of -$103.1 million in 2024.
• Across the five-year window, Profit After Tax plunged 173.26% in 2022 and climbed 21.96% in 2024, its largest moves.
• Year by year, Profit After Tax stood at -$78.0 million in 2022, then tumbled by 131.65% to -$180.8 million in 2023, then climbed by 21.96% to -$141.1 million in 2024, then sank by 74.71% to -$246.5 million in 2025, then sank by 30.07% to -$320.6 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$320.6 million in Q1 2026, -$246.5 million in Q4 2025, and -$212.8 million in Q3 2025.